|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8220 EUR | +17.09% |
|
+54.80% | -46.48% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-11 | AB Science streamlines its portfolio and refocuses on two molecules |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 64.85M | - | - | - | - | |
| 317B | |||||
| 72.79B | |||||
| 9.91B | |||||
| 8.16B | |||||
| 4.51B |
- Stock Market
- Stocks
- AB Stock
- Charts AB Science
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
